FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
Does This News From the FDA Make Eli Lilly a Buy for 2025?
Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's ...
FDA approves weight-loss drug Zepbound to treat sleep apnea
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...
Lilly obesity drug Mounjaro to be offered in Britain's NHS after watchdog nod
Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...
FDA approves anti-obesity drug as first sleep apnea medication
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...
The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
GLP-1 Zepbound is approved as first drug for sleep apnea
The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating ...
NBC Chicago9d
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The Food and Drug ... calorie diet and increased physical activity, the FDA noted in a release. An estimated 80 million patients in the U.S. experience the disease, according to Eli Lilly.